Clinical trials sponsored by Sanofi

Phase breakdown

Conditions studied

Recruiting trials led by Sanofi

• A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States
  NCT07260110 · Phase: Not specified · Ages: 8 Years and older · Sex: All (male and female) · 1 location
• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184944 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · 35 locations
• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07185009 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · 55 locations
• A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
  NCT07556159 · Phase: Not specified · Ages: 6 Years and older · Sex: All (male and female) · 62 locations
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
  NCT06241118 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 150 locations
• A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
  NCT06647069 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
  NCT07053423 · Phase: Phase 4 · Ages: 40 Years to 85 Years · Sex: All (male and female) · 68 locations
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
  NCT06637631 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 139 locations
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
  NCT06867094 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 115 locations
• A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
  NCT06958536 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 66 locations
• A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
  NCT06975722 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 67 locations
• A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
  NCT07688213 · Phase: Phase 2 · Ages: 55 Years to 85 Years · Sex: All (male and female) · 1 location
• A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment
  NCT06192563 · Phase: Not specified · Ages: 6 Months to 17 Years · Sex: All (male and female) · 9 locations
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · 301 locations
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07184996 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · 219 locations
• Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes
  NCT06791291 · Phase: Phase 2 · Ages: 1 Year to 34 Years · Sex: All (male and female) · 11 locations
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  NCT07190209 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 221 locations
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 214 locations
• French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
  NCT06837454 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes
  NCT07380711 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
  NCT07325292 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 40 locations
• Phase 1b/2 Study of IV Sarilumab in Adult With RA
  NCT07704580 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
  NCT07457580 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 14 locations
• Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
  NCT06039241 · Phase: Not specified · Ages: 6 Years and older · Sex: All (male and female) · 55 locations
• Registry for Stage 2 Type 1 Diabetes
  NCT06481904 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 37 locations
• Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
  NCT07247188 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 7 locations
• Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
  NCT07052396 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
  NCT06975865 · Phase: Phase 3 · Ages: 10 Years to 65 Years · Sex: All (male and female) · 53 locations
• The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
  NCT07467564 · Phase: Not specified · Ages: 12 Years and older · Sex: All (male and female) · 7 locations
• The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
  NCT07612878 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female) · 3 locations
• This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
  NCT07290803 · Phase: Not specified · Ages: 12 Years and older · Sex: All (male and female) · 79 locations
• iGlarLixi CGM Study in Chinese T2D Individuals After OADs
  NCT06671587 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials is Sanofi recruiting for?

Sanofi is the lead sponsor of 32 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.